Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants

Class:Id	Reaction:2029992
_displayName	Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants
_doRelease	TRUE
_timestamp	2014-12-03 21:01:42
authored	[InstanceEdit:2105031] Rothfels, K, 2012-02-09
compartment	[Compartment:876] plasma membrane [Compartment:70101] cytosol
created	[InstanceEdit:2029991] Rothfels, K, 2012-01-05
disease	[Disease:1500576] breast cancer [Disease:1500689] cancer [Disease:1500687] stomach cancer
edited	[InstanceEdit:2252592] Rothfels, K, 2012-05-16
entityFunctionalStatus	[EntityFunctionalStatus:5654470] gain_of_function of Overexpressed FGFR2 homodimers [plasma membrane]
input	[DefinedSet:2029963] Overexpressed FGFR2 homodimers [plasma membrane] [Homo sapiens] [DefinedSet:2029965] Tyrosine kinase inhibitors of overexpressed FGFR2 [cytosol] [DefinedSet:2029965] Tyrosine kinase inhibitors of overexpressed FGFR2 [cytosol]
isChimeric	FALSE
literatureReference	[LiteratureReference:2023811] AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor [LiteratureReference:2023815] Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
modified	[InstanceEdit:2060793] Rothfels, K, 2012-01-16 [InstanceEdit:2077462] Rothfels, K, 2012-01-27 [InstanceEdit:2105657] Rothfels, K, 2012-02-10 [InstanceEdit:2123588] Rothfels, K, 2012-02-14 [InstanceEdit:2156426] Rothfels, K, 2012-02-28 [InstanceEdit:2248846] Rothfels, K, 2012-05-15 [InstanceEdit:2275109] Rothfels, K, 2012-05-25 [InstanceEdit:5654550] Rothfels, Karen, 2014-12-03 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants
output	[Complex:2029966] Overexpressed FGFR2:TKIs [plasma membrane] [Homo sapiens]
precedingEvent	[Reaction:2029988] Dimerization of overexpressed FGFR2 [Homo sapiens]
releaseDate	2012-06-12
reviewed	[InstanceEdit:2248845] Ezzat, S, 2012-05-15
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:2295273] R-HSA-2029992.2
summation	[Summation:2060746] Amplified FGFR2 has been shown to be a potential target for ...
(hasEvent)	[Pathway:2023837] Signaling by FGFR2 amplification mutants [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants (2029992)